Premium
Expression of CD 70 in nasal natural killer/ T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD 27
Author(s) -
Yoshino Kazumi,
Kishibe Kan,
Nagato Toshihiro,
Ueda Seigo,
Komabayashi Yuki,
Takahara Miki,
Harabuchi Yasuaki
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12136
Subject(s) - biology , lymphoma , natural killer cell , antibody , cell culture , immunotherapy , t cell , cancer research , microbiology and biotechnology , immunology , cytotoxic t cell , in vitro , immune system , biochemistry , genetics
Summary Nasal natural killer ( NK )/ T cell lymphoma ( NNKTL ) is associated with E pstein– B arr virus ( EBV ). The present study analysed gene expression patterns of the NNKTL cell lines SNK 6, SNK 1 and SNT 8, which are positive for EBV and latent membrane protein ( LMP )‐1, using a complementary DNA array analysis. We found that CD 70 was specifically expressed in SNK 6 and SNT 8. Reverse transcription polymerase chain reaction and flow cytometric analyses confirmed that CD 70 was expressed in all 3 NNKTL cell lines, but not in the other EBV ‐positive NK ‐cell lines. In vitro studies showed that NNKTL cell lines proliferated, in a dose‐dependent fashion, in response to exogenous soluble CD 27, which is the ligand for CD 70. In NNKTL patients, we confirmed that the CD 70 was expressed on the lymphoma cells in NNKTL tissues and that soluble CD 27 was present in sera at higher levels as compared to healthy individuals. Finally, complement‐dependent cytotoxicity assay showed that anti‐ CD 70 antibody mediated effective complement‐dependent killing of NNKTL cells and the affected target CD 70 expression on the cells. These results suggest that CD 70 acts as a functional receptor binding to soluble CD 27, resulting in lymphoma progression and that immunotherapy using anti‐ CD 70 antibody may be a potential candidate for treatment for NNKTL .